Luka from Switzerland

Registered at the short selling broker Skilling, 2 minutes ago.

» Try Skilling you too
69% of retail CFD accounts lose money.
Don't show again

Novartis AG (NVS) shares information

Novartis AG


24h Change

0.02 %

NVS

Live rate: Market closed

Stock data per Friday 23 Oct, 2020

NVS
New York Stock Exchange
84.41
84.65
84.43
0.02 (+ 0.02%)
US Market is closed

Live Stock price in graph for Novartis AG (NVS)

  • Latest Volume

    810,594 (-37.83 %)

  • Volume prev. day

    1,303,932

  • Avg. daily volume

    1,787,929

  • Market cap

    186,142,286,389

  • P/E ratio

    26.62

  • Today high

    84.88

  • Today low

    84.12

  • 52 week high

    99.84

  • 52 week low

    69.18

  • YTD Change

    n/a

Quick links

Broker recommendations for Novartis AG

The Novartis AG stock is rated at 1.5 (on a scale 1-3, where 1 is ‘strong buy‘ and 3 is ‘strong sell‘) from Wednesday 30 September, 2020 by a total of 21 brokers. This means that the consensus of the 21 different brokers is leaning toward to overweight (moderate buy).

Sell
2 (9.52%)
Underweight
0 (0%)
Hold
5 (23.81%)
Overweight
3 (14.29%)
Buy
11 (52.38%)

Price target by analysts

The 17 latest analyst estimates, per Wednesday 21 October, 2020, show the following high, low and average price targets.
Target Average: 105 USD
Target High: 121.34 USD
Target Low: 82.52 USD

 

Latest news about Novartis AG

Below you can find the most recent news posts about Novartis AG, primarily from US and UK based news sources.

Novartis (NVS) Set to Announce Earnings on Tuesday

Sunday, 25 October 2020, 02:22:41
Novartis (NYSE:NVS) will post its quarterly earnings results before the market opens on Tuesday, October 27th. Analysts expect Novartis to post earnings of $1.41 per share for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link. NVS opened at $84.43 on Friday. The company has a […]
— The Lincolnian


Novartis AG (NYSE:NVS) Receives Average Recommendation of “Hold” from Brokerages

Saturday, 24 October 2020, 05:10:56
Novartis AG (NYSE:NVS) has received a consensus rating of “Hold” from the eleven brokerages that are presently covering the stock, MarketBeat reports. Three equities research analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and six have issued a buy recommendation on the company. The average 12-month target price […]
— US Banking News


Head & Neck Cancer Drugs Market Top-Companies, Future-Growth, Regional Analysis, Business-Opportunities 2027 | Bristol-Myers Squibb, ARMO Biosciences, Fortress Biotech, Genentech, Novartis

Friday, 23 October 2020, 09:40:50
Increase in incidence of head & neck cancer play a major role in the growth of the head & neck cancer drugs market. Furthermore, increase in use of combination therapy and growth in demand for target immune therapy in the
— OpenPR


Active Pharmaceutical Ingredients (API) Market Size 2020 Industry Price Trend, Industry Outlook, Business Growth, Report Latest Research| Pfizer Inc., Novartis AG, Sanofi, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company

Friday, 23 October 2020, 09:21:18
The Active Pharmaceutical Ingredients (API) Market Research Report delivers all-inclusive analysis of the market structure along with forecast of the diverse segments and sub-segments of the market. Active Pharmaceutical Ingredients (API) Market 2020 Industry Research Report is an in-depth and
— OpenPR


THE DIGITAL THERAPEUTICS EXPLAINER: How digital treatments could be a $9 billion opportunity by 2025

Thursday, 22 October 2020, 17:04:00
Summary List Placement This is a preview of The Digital Therapeutics research report from Business Insider Intelligence. Purchase this report. Business Insider Intelligence offers even more healthcare coverage with Digital Health Pro. Subscribe today to receive industry-changing digital health news and analysis to your inbox. A new class of medicine — digital therapeutics (DTx) — has emerged, offering a novel means of treating the swelling number of patients with chronic diseases and keeping associated costs down. Digital therapeutics deliver evidence-based therapies via software — often in the form of consumer-facing mobile health apps — that replace or complement the existing treatment of a disease. They diverge from the broader digital health market in that they must be approved by regulatory bodies — and displaying proof-of-concept is at the core of their model. DTx vendors leverage their tech to treat chronic conditions, which gobble up the lion’s share of the US’ healthcare spending: Business Insider Intelligence estimates that the US shelled out up to $3.3 trillion on chronic disease in 2018.
— Business Insider


Trading broker recommendation

We recommend that you check out Capital.com as they have a very good selection of stocks available for both going short and long.

Rating: 9.57/10
Minimum deposit: €/$ 20
Description: Capital.com offer a large number of stocks for trading. Register an account today and check if they have NVS available or trade one of the many other CFD stocks they have.
Risk warning: 75% of retail investor accounts lose money when trading CFDs with Capital.